Faculty profile

Mark Minden

ResearcherMedical BiophysicsUniversity of Toronto

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Toronto directory, so their courses may be missing. Find their university profile.

Mark Minden

Researcher

Medical Biophysics

Health Sciences

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
14 publications in the last five years, latest in 2026.
Principal investigator on 4 research grants (4 CIHR), most recently in 2020.
Supervised 1 trainee who won CIHR awards, most recently in 2010.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Acute Myeloid Leukemia Bone Marrow Cxcr4 Fluorescent Microscopy Hypoxia Hypoxia Activated Drugs Intravital Imaging Leukemia

Latest papers

A multimodal atlas for immunotherapeutic targeting of AML surface heterogeneity.
iScience · 2026
IFN-γ drives long-term bone marrow niche dysfunction following doxorubicin-based chemotherapy.
Blood · 2026
Adult Patients with Philadelphia-Positive B-Cell Acute Lymphoblastic Leukemia Treated with a Pediatric-Inspired Multiagent Chemotherapy Regimen, in Combination with a TKI, Do Not Require Routine alloSCT.
Current oncology (Toronto, Ont.) · 2026

All 49 publications

Latest funding

Discovery of sex-dimorphic leukemia-protective programs embedded in human hematopoietic stem cells
CIHR · 2025 · Co-investigator
$1,591,200
Understanding the Interaction of Acute Myeloid Leukemia with the Bone Marrow Microenvironment: Elucidating New Therapeutic Targets Through In Vivo Imaging
CIHR · 2020 · Principal investigator
$612,000
Mutant nucleophosmin AML a heterogeneous disease: characterization and drug sensitivity.
CIHR · 2017 · Nominated PI
$688,500

All 9 grants and awards

49 publications.

A multimodal atlas for immunotherapeutic targeting of AML surface heterogeneity.

Ung M, Etchin J, Halfond A, DiFazio J, Keschner Y, Pyclik A, Campbell A, Wang R, Silva M, Gjeci B, Montalbano A, Williams R, Mundelboim G, Arruda A, Minden M, Scherer J, Chakraborty T, Ge HG, Lydeard JR

iScience2026

DOI: 10.1016/j.isci.2026.115337 PMID: 41959675

IFN-γ drives long-term bone marrow niche dysfunction following doxorubicin-based chemotherapy.

Li X, Aguilar-Navarro AG, Nader M, Jahangiri S, Lee HS, Edun G, Gower M, Yang D, Fernandez M, Lin B, Oh D, Farhat S, Phillips DM, Bartman S, Murray D, Kaszuba C, Kossinna P, Kamath M, Whyne C, Schwartz G, Bajaj J, Kislinger T, Zhou BO, Coutu D, Akens M, Changoor A, Mallevaey T, Gaiti F, Jones C, Naik S, Minden M, Arruda A, Hitzler J, Lee KJ, Kim YM, Adams RH, Sivara KK, Tikhonova AN

Blood2026

DOI: 10.1182/blood.2025030946 PMID: 42008378

Adult Patients with Philadelphia-Positive B-Cell Acute Lymphoblastic Leukemia Treated with a Pediatric-Inspired Multiagent Chemotherapy Regimen, in Combination with a TKI, Do Not Require Routine alloSCT.

Eng DZS, Khadadah F, Perusini MA, Al-Shaibani E, Atenafu EG, Bankar A, Davidson M, Richard-Carpentier G, Maze D, Yee K, Schimmer A, Gupta V, Chan S, Kim DDH, Schuh A, Minden M, Sibai H

Current oncology (Toronto, Ont.)2026

DOI: 10.3390/curroncol33020127 PMID: 41744891

An inflammatory state defines a high-risk T-lineage acute lymphoblastic leukemia subgroup.

Gower M, Li X, Aguilar-Navarro AG, Lin B, Fernandez M, Edun G, Nader M, Rondeau V, Arruda A, Tierens A, Eames Seffernick A, Pölönen P, Durocher J, Wagenblast E, Yang L, Lee HS, Mullighan CG, Teachey D, Rashkovan M, Tremblay CS, Herranz D, Itkin T, Loghavi S, Dick JE, Schwartz G, Perusini MA, Sibai H, Hitzler J, Gruber TA, Minden M, Jones CL, Dolgalev I, Jahangiri S, Tikhonova AN

Science translational medicine2025

DOI: 10.1126/scitranslmed.adr2012 PMID: 39742502

Pharmacological inhibition of Peroxisome Proliferation-Activated Receptor Delta (PPARδ) imparts selective leukemia cell death

Yang Y, Parfenova E, Vrdoljak N, Minden M, Luc J, Doxey AC, Spagnuolo PA

Cancer & Metabolism20254 citations

DOI: 10.1186/s40170-025-00402-5

Diagnostic Accuracy in Detecting Fungal Infection with Ultra-Low-Dose Computed Tomography (ULD-CT) Using Filtered Back Projection (FBP) Technique in Immunocompromised Patients.

D'Errico L, Ghali A, Pakkal M, McInnis M, Mehrez H, Schuh AC, Kuruvilla JG, Minden M, Paul NS

Journal of clinical medicine2024

DOI: 10.3390/jcm13061704 PMID: 38541929

Utilizing insights of DNA repair machinery to discover MMEJ deletions and novel mechanisms.

Kadam A, Shilo S, Naor H, Wainstein A, Brilon Y, Feldman T, Minden M, Kaushansky N, Chapal-Ilani N, Shlush L

Nucleic acids research2024

DOI: 10.1093/nar/gkae1132 PMID: 39607705

Mutations in myeloid transcription factors and activated signaling genes predict chronic myeloid leukemia outcomes.

Perusini MA, Žáčková D, Kim T, Pagnano K, Pavlovsky C, Ježíšková I, Kvetková A, Jurček T, Kim J, Yoo Y, Yi S, Lee H, Kim KH, Chang M, Capo-Chichi JM, Medeiros JJF, Arruda A, Minden M, Zhang Z, Abelson S, Mayer J, Hwan Kim DD

Blood advances2024

DOI: 10.1182/bloodadvances.2023012127 PMID: 38447114

Flow cytometry-based measurable residual disease (MRD) analysis identifies AML patients who may benefit from allogeneic hematopoietic stem cell transplantation.

Lucero J, Alhumaid M, Novitzky-Basso I, Capo-Chichi JM, Stockley T, Gupta V, Bankar A, Chan S, Schuh AC, Minden M, Mattsson J, Kumar R, Sibai H, Tierens A, Kim DDH

Annals of hematology2024

DOI: 10.1007/s00277-024-05639-6 PMID: 38291275

Long-term survival and functional outcomes of critically ill patients with hematologic malignancies: a Canadian multicenter prospective study

Munshi L, Dumas G, Rochwerg B, Shoukat F, Detsky M, Fergusson DA, Ferreyro BL, Heffernan P, Herridge M, Magder S

Intensive Care Medicine202459 citations

DOI: 10.1007/s00134-024-07349-z

Something wrong or missing on this profile? Suggest a correction

Mark Minden

Research

Latest papers

Latest funding

A multimodal atlas for immunotherapeutic targeting of AML surface heterogeneity.

IFN-&#x3b3; drives long-term bone marrow niche dysfunction following doxorubicin-based chemotherapy.

Adult Patients with Philadelphia-Positive B-Cell Acute Lymphoblastic Leukemia Treated with a Pediatric-Inspired Multiagent Chemotherapy Regimen, in Combination with a TKI, Do Not Require Routine alloSCT.

An inflammatory state defines a high-risk T-lineage acute lymphoblastic leukemia subgroup.

Pharmacological inhibition of Peroxisome Proliferation-Activated Receptor Delta (PPARδ) imparts selective leukemia cell death

Diagnostic Accuracy in Detecting Fungal Infection with Ultra-Low-Dose Computed Tomography (ULD-CT) Using Filtered Back Projection (FBP) Technique in Immunocompromised Patients.

Utilizing insights of DNA repair machinery to discover MMEJ deletions and novel mechanisms.

Mutations in myeloid transcription factors and activated signaling genes predict chronic myeloid leukemia outcomes.

Flow cytometry-based measurable residual disease (MRD) analysis identifies AML patients who may benefit from allogeneic hematopoietic stem cell transplantation.

Long-term survival and functional outcomes of critically ill patients with hematologic malignancies: a Canadian multicenter prospective study

Frequent collaborators

Aaron Schimmer

Steven Chan

Armand Keating

Rajat Kumar

Jonas Mattsson

Tracy Stockley

Fei-Fei Liu

Sangeeta Mehta

John Kuruvilla

Rinat Nissim

Gregory Schwartz

Laveena Munshi

Mary Gospodarowicz

Zhaolei Zhang

Gary Rodin

Camilla Zimmermann

Brent Williams

Johann Hitzler

Wei Wang

Sheldon Magder

Michael Detsky

Federico Gaiti

Adele Changoor

Kristin Hope

Salman Qureshi

Michael Sklar

John Dick

Barry Rosen

Kolja Eppert

Thierry Mallevaey

Margarete Akens

Bram Rochwerg

Janusz Pawliszyn

Andrew Doxey

Thomas Kislinger

Cari Whyne

David Hedley

Cheryl Arrowsmith

IFN-γ drives long-term bone marrow niche dysfunction following doxorubicin-based chemotherapy.